2. Metabolic Enzyme/Protease Apoptosis
  3. Cytochrome P450 Apoptosis
  4. CYP4Z1-IN-3

CYP4Z1-IN-3 is a selective CYP4Z1 inhibitor with a human IC50 of 55.3 nM. CYP4Z1-IN-3 inhibits breast cancer cell migration and induces apoptosis. CYP4Z1-IN-3 can be used for the research of breast cancer.

For research use only. We do not sell to patients.

CYP4Z1-IN-3

CYP4Z1-IN-3 Chemical Structure

CAS No. : 3106166-49-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CYP4Z1-IN-3 Related Antibodies

Top Publications Citing Use of Products

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CYP4Z1-IN-3 is a selective CYP4Z1 inhibitor with a human IC50 of 55.3 nM. CYP4Z1-IN-3 inhibits breast cancer cell migration and induces apoptosis. CYP4Z1-IN-3 can be used for the research of breast cancer[1].

IC50 & Target[1]

CYP4Z1

55.3 nM (IC50)

In Vitro

CYP4Z1-IN-3 (Compound C8) (0.1-10 μM) potently inhibits CYP4Z1 enzyme activity in lysates from CYP4Z1-overexpressing HEK293T cells with an IC50 of 55.3 nM[1].
CYP4Z1-IN-3 exhibits high isoform selectivity for CYP4Z1 over human CYP2C9, CYP2C19, CYP2D6, and CYP3A4[1].
CYP4Z1-IN-3 (60 min) exhibits favorable metabolic stability in CD-1 mouse liver microsomes, with a half-life of 62.4 min and low intrinsic clearance[1].
CYP4Z1-IN-3 (3 h) shows excellent plasma stability in CD-1 mouse plasma, with a half-life exceeding 3.0 h, while it exhibits poor stability in human plasma[1].
CYP4Z1-IN-3 (0.01-100 μM; 48 h) does not exhibit significant cytotoxicity in MCF-7 breast cancer cells, MDA-MB-231 breast cancer cells, or normal MCF-10A mammary epithelial cells at concentrations up to 100 μM after 48 h of incubation[1].
CYP4Z1-IN-3 (0.5-12.5 μM) concentration-dependently reduces expression of stemness markers ALDH1A1, SOX2, and Nanog in CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells, but not in CYP4Z1-negative 4T1 cells[1].
CYP4Z1-IN-3 (0.5-12.5 μM) concentration-dependently reduces the CD44+/CD24− breast cancer stem cell subpopulation in CYP4Z1-expressing MCF-7 and MDA-MB-231 cells, but not in CYP4Z1-negative 4T1 cells[1].
CYP4Z1-IN-3 (0.5-12.5 μM) dose-dependently suppresses mammosphere formation in CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells, but not in CYP4Z1-negative 4T1 cells[1].
CYP4Z1-IN-3 (0.5-12.5 μM; 24-48 h) concentration-dependently inhibits the migratory capacity of CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells in wound healing assays[1].
CYP4Z1-IN-3 (0.5-12.5 μM; 24-48 h) inhibits the invasive capacity of CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells in Transwell assays[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CYP4Z1-IN-3 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: MCF-7, MDA-MB-231, MCF-10A cells
Concentration: 0.01 μM; 0.1 μM; 1 μM; 10 μM; 100 μM
Incubation Time: 48 h
Result: Showed no significant cytotoxicity in MCF-7, MDA-MB-231, or normal MCF-10A cells at concentrations up to 100 μM.

Cell Migration Assay [1]

Cell Line: MCF-7, MDA-MB-231 breast cancer cells
Concentration: 0.5 μM; 2.5 μM; 12.5 μM
Incubation Time: 24 h; 48 h
Result: Suppressed the migratory capacity of MCF-7 and MDA-MB-231 cells in a concentration-dependent and significant manner.

Cell Invasion Assay[1]

Cell Line: MCF-7, MDA-MB-231 breast cancer cells
Concentration: 0.5 μM; 2.5 μM; 12.5 μM
Incubation Time: 24 h; 48 h
Result: Inhibited the invasive capacity of CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells in Transwell assays
In Vivo

CYP4Z1-IN-3 (Compound C8) (100-800 mg/kg; p.o.; single dose) does not cause acute toxicity in BALB/c mice[1].
CYP4Z1-IN-3 (10 mg/kg; i.v.; every three days for three week) reduces the number of lung metastatic nodules in a breast cancer lung metastasis model in BALB/c-nude mice without causing significant organ toxicity[1].
CYP4Z1-IN-3 attenuates the tumor-initiating capacity and stemness of breast cancer cells in immunodeficient mice, reducing tumor formation rate, tumor weight, stem cell frequency, stemness marker expression, and proliferation while increasing apoptosis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (SPF-grade; male and female)[1]
Dosage: 100 mg/kg; 200 mg/kg; 400 mg/kg; 800 mg/kg
Administration: p.o.; single dose
Result: Showed no significant changes in body weight over 7 days.
Showed no significant changes in general health indicators over 7 days.
Animal Model: Balb/c-nude (female; 4–6 weeks old; injected intravenously with 5 × 106 MDA-MB-231 cells to establish a breast cancer lung metastasis model)[1]
Dosage: 10 mg/kg
Administration: i.v.; every three days for three week
Result: Reduced the number of lung metastatic nodules.
Exhibited no significant organ toxicity.
Molecular Weight

322.40

Formula

C19H22N4O
CAS No.
SMILES

CCCCNC(CC1=CC=C(C=C1)CN2C=NC3=C2C=CN=C3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CYP4Z1-IN-3 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CYP4Z1-IN-33106166-49-5Cytochrome P450ApoptosisCYPsMCF-7 breast cancer cellsMDA-MB-231 breast cancer cellsCYP2C19breast cancerCD-1 mouse liver microsomesHEK293T cellsCYP4Z1CYP3A4CYP2D6CYP2C9Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CYP4Z1-IN-3
Cat. No.:
HY-183756
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.